Updates are available Correction dated 2020-05-18
Click to view Correction: https://doi.org/10.1038/s41467-020-16344-z
-
Authors
Färkkilä, Anniina http://orcid.org/0000-0002-3558-6617
Gulhan, Doga C.
Casado, Julia http://orcid.org/0000-0002-3662-8794
Jacobson, Connor A. http://orcid.org/0000-0002-0299-3451
Nguyen, Huy http://orcid.org/0000-0002-4424-1047
Kochupurakkal, Bose
Maliga, Zoltan
Yapp, Clarence http://orcid.org/0000-0003-1144-5710
Chen, Yu-An http://orcid.org/0000-0001-7228-4696
Schapiro, Denis
Zhou, Yinghui
Graham, Julie R. http://orcid.org/0000-0002-3909-5321
Dezube, Bruce J.
Munster, Pamela http://orcid.org/0000-0002-2074-0984
Santagata, Sandro http://orcid.org/0000-0002-7528-9668
Garcia, Elizabeth
Rodig, Scott
Lako, Ana
Chowdhury, Dipanjan http://orcid.org/0000-0001-5645-3752
Shapiro, Geoffrey I.
Matulonis, Ursula A.
Park, Peter J. http://orcid.org/0000-0001-9378-960X
Hautaniemi, Sampsa http://orcid.org/0000-0002-7749-2694
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Swisher, Elizabeth M. http://orcid.org/0000-0003-2331-0434
D’Andrea, Alan D. http://orcid.org/0000-0001-6168-6294
Konstantinopoulos, Panagiotis A.
-
Funding
Funding for this research was provided by:
EIF | Stand Up To Cancer (SU2C-AACR-DT16-15)
- License Information
-
More Information
Article History
Received: 27 September 2019
Accepted: 26 February 2020
First Online: 19 March 2020
Change Date: 18 May 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: J.G. and Y.Z. were previously employed by TESARO, and now is a GSK employee. B.D. was an employee of Tesaro at the time of the work related to this manuscript. G.I.S. receives research funding from Merck & Co. S.S. is a consultant for RareCyte, Inc. P.K.S. is a member of the SAB or Board of Directors of Applied Biomath and RareCyte Inc and has equity in these companies. In the last 5 years, the Sorger lab has received research funding from Novartis and Merck. Sorger declares that none of these relationships are directly or indirectly related to the content of this manuscript. For the SigMA algorithm, a patent application titled “Systems and methods for classifying tumors” has been filed under the Patent Cooperation Treaty (PCT) by authors D.G. and P.P. on 18 September, 2019 following a provisional patent application filed on 24 September, 2018. U.M. has served as a consultant for Merck and has been the North America PI of the NOVA study funded by TESARO. P.K. and A.D.D’A. have served as consultants/members of advisory boards for Merck and Tesaro/GSK. Other authors have no competing interests to declare.
